| Nomenclature | CD33 | sialic acid binding Ig like lectin 6 | sialic acid binding Ig like lectin 8 | sialic acid binding Ig like lectin 10 |
| Common abbreviation | SIGLEC3 | – | SIGLEC8 | SIGLEC10 |
| HGNC, UniProt | CD33, P20138 | SIGLEC6, O43699 | SIGLEC8, Q9NYZ4 | SIGLEC10, Q96LC7 |
| Selective agonists | – | – | – | MK-7110 [162] |
| Antibodies | lintuzumab (Binding) (pKd~10) [24], gemtuzumab ozogamicin (Binding) [17] | – | – | – |
| Comments | – | SIGLEC6 binds sialyl-TN glycans and leptin. It was considered as a therapeutic target for the treatment of eosinophil- and mast cell-mediated inflammation [74, 99, 117]. However, development of the anti-SIGLEC6 monoclonal antibody AK006 was discontinued at phase 1 due to lack of efficacy in patients with moderate-to-severe chronic spontaneous urticaria. | – | – |
Official websites use .gov
A
.gov website belongs to an official
government organization in the United States.
Secure .gov websites use HTTPS
A lock (
) or https:// means you've safely
connected to the .gov website. Share sensitive
information only on official, secure websites.